Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Jun 1;10(2):147-152.
doi: 10.4274/jcrpe.5117. Epub 2018 Feb 28.

Effectiveness of Continuous Subcutaneous Insulin Infusion Pump Therapy During Five Years of Treatment on Metabolic Control in Children and Adolescents with Type 1 Diabetes Mellitus

Özlem Korkmaz  1 , Günay Demir  1 , Hafize Çetin  1 , İlkin Mecidov  1 , Yasemin Atik Altınok  1 , Samim Özen  1 , Şükran Darcan  1 , Damla Gökşen  1
Affiliations
Comparative Study

Effectiveness of Continuous Subcutaneous Insulin Infusion Pump Therapy During Five Years of Treatment on Metabolic Control in Children and Adolescents with Type 1 Diabetes Mellitus

Özlem Korkmaz et al. J Clin Res Pediatr Endocrinol. .

Abstract

Objective: To compare continuous subcutaneous insulin infusion (CSII) therapy with multiple daily insulin (MDI) therapy on metabolic control in children and adolescents with type 1 diabetes mellitus (T1DM) over the long term.

Methods: Fifty-two T1DM patients treated with CSII and monitored for at least one year prior to and at least five years following CSII were included. Thirty-eight age and sex-matched MDI controls with a 5-year follow up were recruited.

Results: Mean age of the subjects, duration of diabetes and CSII therapy were 17.0±4.8 years, 10.7±2.8 years and 7.7±1.5 years respectively. Mean hemoglobin A1c (HbA1c) in the year prior to CSII, during the first year of treatment and after 5 years of CSII were 7.3±1% (56 mmol/mol), 7.0±0.7% (53 mmol/mol) and 7.8±1.3% (62 mmol/mol) respectively. Initial and 5-year mean HbA1C levels of controls were 7.9±1.08% and 8.6±1.8%. Mean HbA1c values were significantly lower in those receiving CSII therapy throughout follow-up. Basal and total insulin doses were significantly lower in the CSII group at all times. HbA1c was compared between subjects by age (0-5, 6-11 and 12-18 years) with no significant difference between them.

Conclusion: Although CSII mean HbA1c values exceeded accepted good metabolic control limits after 5 years, CSII produces better HbA1c control at all times and in all age groups compared to MDI.

Keywords: Type 1 diabetes mellitus; continuous subcutaneous insulin infusion pump therapy; multiple daily insulin therapy; HbA1c.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Comparison of the mean hemoglobin A1c values between the two treatment groups during the five year follow-up period HbA1c: hemoglobin A1c
Figure 2
Figure 2. Mean hemoglobin A1c levels in the continuous subcutaneous insulin infusion patients by age group during the five year follow-up period HbA1c: hemoglobin A1c
Figure 3
Figure 3. Comparison of the daily insulin dose between the two treatment groups during the five year follow-up period CSII: continuous subcutaneous insulin infusion, MDI: multiple daily insulin
Figure 4
Figure 4. Body mass index standard deviation score values during the five-year follow-up period CSII: continuous subcutaneous insulin infusion, MDI: multiple daily insulin, BMI: body mass score, SDS: standard deviation score
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324:705. - PMC - PubMed
    1. Pickup JC. The evidence base for diabetes technology: appropriate and inappropriate meta-analysis. J Diabet Sci Technol. 2013;7:1567–1574. - PMC - PubMed
    1. Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for Type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010;CD005103 - PubMed
    1. Chiang JL, Kirkman MS, Laffel LM, Peters AL Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034–2054. - PMC - PubMed
    1. Giménez M, Conget I, Jansà M, Vidal M, Chiganer G, Levy I. Efficacy of continuous subcutaneous insulin infusion in Type 1 diabetes: a 2-year perspective using the established criteria for funding from a National Health Service. Diabet Med. 2007;24:1419–1423. - PubMed

Publication types